BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34275066)

  • 1. Optimization of lymphapheresis for manufacturing autologous CAR-T cells.
    Yamanaka I; Yamauchi T; Henzan T; Sakoda T; Miyamoto K; Mishima H; Ono H; Koga Y; Nakashima Y; Kato K; Miyamoto T; Mizuno S; Ogawa Y; Ohga S; Akashi K; Maeda T; Kunisaki Y
    Int J Hematol; 2021 Oct; 114(4):449-458. PubMed ID: 34275066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous lymphapheresis for the production of chimeric antigen receptor T cells.
    Allen ES; Stroncek DF; Ren J; Eder AF; West KA; Fry TJ; Lee DW; Mackall CL; Conry-Cantilena C
    Transfusion; 2017 May; 57(5):1133-1141. PubMed ID: 28236305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy.
    Jo T; Yoshihara S; Hada A; Arai Y; Kitawaki T; Ikemoto J; Onomoto H; Sugiyama H; Yoshihara K; Obi N; Matsui K; Niwa N; Nakagawa Y; Kanda J; Kondo T; Saida S; Kato I; Hiramatsu H; Adachi S; Takita J; Takaori-Kondo A; Nagao M
    Transplant Cell Ther; 2022 Jul; 28(7):365.e1-365.e7. PubMed ID: 35460928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Challenges in Providing Good Leukapheresis Products for Manufacturing of CAR-T Cells for Patients with Relapsed/Refractory NHL or ALL.
    Korell F; Laier S; Sauer S; Veelken K; Hennemann H; Schubert ML; Sauer T; Pavel P; Mueller-Tidow C; Dreger P; Schmitt M; Schmitt A
    Cells; 2020 May; 9(5):. PubMed ID: 32429189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients.
    Harrer DC; Heidenreich M; Fante MA; Müller V; Haehnel V; Offner R; Burkhardt R; Herr W; Edinger M; Wolff D; Thomas S; Brosig A
    Transfusion; 2022 Aug; 62(8):1602-1611. PubMed ID: 35851959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.
    Schultz L; Patel S; Davis KL; Ramakrishna S; Sahaf B; Bhatia N; Baggott C; Erickson C; Majzner RG; Oak J; Bertaina A; Mackall C; Feldman S
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.
    Ceppi F; Rivers J; Annesley C; Pinto N; Park JR; Lindgren C; Mgebroff S; Linn N; Delaney M; Gardner RA
    Transfusion; 2018 Jun; 58(6):1414-1420. PubMed ID: 29536556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients.
    Jarisch A; Rettinger E; Sörensen J; Klingebiel T; Schäfer R; Seifried E; Bader P; Bonig H
    J Clin Apher; 2020 Sep; 35(5):398-405. PubMed ID: 32750197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical experience of leukapheresis for CD19 CAR-T cell therapy].
    Jo T; Yoshihara S; Arai Y; Ikemoto J; Onomoto H; Sugiyama H; Yoshihara K; Matsui K; Niwa N; Nakagawa Y; Kitawaki T; Kanda J; Takaori-Kondo A; Nagao M
    Rinsho Ketsueki; 2021; 62(3):163-169. PubMed ID: 33828008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An international survey on the management of patients receiving CAR T-cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT.
    Hayden PJ; Sirait T; Koster L; Snowden JA; Yakoub-Agha I
    Curr Res Transl Med; 2019 Aug; 67(3):79-88. PubMed ID: 31182380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukapheresis and Tisagenlecleucel Manufacturing Outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic Leukemia.
    Fong D; Tiwari R; Acker C; Clough L; Willert J
    Transplant Cell Ther; 2023 Sep; 29(9):579.e1-579.e10. PubMed ID: 37311511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients.
    Wang Y; Li H; Song X; Qi K; Cheng H; Cao J; Shi M; Yan Z; Jing G; Pan B; Sang W; Wang X; Zhao K; Chen C; Chen W; Zheng J; Li Z; Xu K
    Int J Lab Hematol; 2021 Apr; 43(2):250-258. PubMed ID: 33112046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GMP CAR-T cell production.
    Gee AP
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):126-134. PubMed ID: 29909913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility of leukapheresis for CAR T-cell production in heavily pre-treated pediatric patients.
    Hutt D; Bielorai B; Baturov B; Z'orbinski I; Ilin N; Adam E; Itzhaki O; Besser MJ; Toren A; Jacoby E
    Transfus Apher Sci; 2020 Aug; 59(4):102769. PubMed ID: 32414613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell counts in peripheral blood at leukapheresis predict responses to subsequent CAR-T cell therapy.
    Wada F; Jo T; Arai Y; Kitawaki T; Mizumoto C; Kanda J; Nishikori M; Yamashita K; Nagao M; Takaori-Kondo A
    Sci Rep; 2022 Nov; 12(1):18696. PubMed ID: 36333521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous cryopreserved leukapheresis cellular material for chimeric antigen receptor-T cell manufacture.
    Tyagarajan S; Schmitt D; Acker C; Rutjens E
    Cytotherapy; 2019 Dec; 21(12):1198-1205. PubMed ID: 31837735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies.
    Schwab RD; Bedoya DM; King TR; Levine BL; Posey AD
    Methods Mol Biol; 2020; 2086():203-211. PubMed ID: 31707678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy.
    Carbonell D; Monsalvo S; Catalá E; Pérez-Corral A; Villegas C; Falero C; Ruano G; Martinez M; Kwon M; Muñoz-Martínez C; Díez-Martín JL; Gayoso J; Anguita J
    Blood Transfus; 2024 May; 22(3):239-245. PubMed ID: 38063787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.